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Precise assessment of HER2 gene status as an important biomarker plays a 
significant role in identifying the eligible patients for Trastuzumab therapy 
and determining their clinical outcomes. In this study, the researchers 
assigned HER2 amplification status in invasive breast cancer specimens by 
Fluorescence in Situ Hybridization (FISH) and determined its association 
with other clinical features. Formalin-fixed paraffin embedded tumor tissue 
specimens of 46 patients with invasive breast cancer were collected from 
November 2011 till May 2012. HER2status was evaluated by FISH. The 
Zytolight SPEC HER2/CEN17 dual color probe kit was applied for 
assessment of HER2status. HER2 gene amplification was defined as 
HER2/CEP17 ratio>2.2.The  association between HER2status and clinical 
features like tumor grade, tumor type, tumor size, axillary lymph node 
involvement and age of patient was done using Chi squared test at the 0.05 
level of significance (p value). Amplification of HER2 gene was detected 
in twelve cases (26%). On statistical analysis HER2status showed 
correlation with tumor grade (p=0.02).There was no correlation between 
HER2status and tumor type, tumor size, lymph node status and age of 
patients. The results of this study are consonant with the findings of other 
studies about the presence of HER2 gene amplification in invasive breast 
cancer. Statistical analysis showed patients with HER2 amplified gene 
have tumors with higher grade. In these patients the probability of 
increased proliferation and metastasis is high therefore evaluation of HER2 
gene amplification status in breast cancer patients specially in high grade 
tumor with an accurate method such as FISH is essential. 
  © 2015 PSCI Publisher All rights reserved. 
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Introduction  
Breast cancer is the second most common cancer after lung cancer in the world(Jemal et al., 2010) and is the fifth 
cause of cancer related  death(Hutchinson, 2010)Breast cancers are classified based on  several factors such as tumor grade, 
tumor stage, tumor type , tumor size, lymph node status and others (Alizart et al., 2012). The biomarkers used for breast cancer 
classification include estrogen receptor (ER), progersterone receptor (PR) and human epidermal growth factor receptor 2 
(HER2) (Fitzgibbons et al., 2000).Among these factors, the HER2 gene status or its protein expression has both a predictive 
and prognostic value (Henry and Hayes, 2006).The HER2 gene is located on chromosome 17q21 and its  product is a 
transmembrane growth factor receptor . This receptor is involved in the cellular signaling  regulating growth and development 
(Popescu et al., 1989). The HER2 protein over expression after gene amplification in breast cancer results in inordinate 
activation of the signaling pathways (Yarden, 2001). Increased HER2 activity leads to in resistance to conventional therapy 
(Colomer et al., 2007; Ross  et al., 2009 ). Trastuzumab (Herceptin) is the most widely used therapeutic option in breast cancer  
patients with HER2 gene amplification( Ross  et al., 2009). Trastuzumab is a recombinant humanized monoclonal antibody 
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against the extracellulardomain of HER2. Trastuzumab is useful only in patients with HER2 gene amplification or protein 
overexpression (Mass et al., 2005). Trastuzumab treatment in HER2 negative cancer cases associated with side effects such as 
cardiotoxicity (Moelans et al., 2011). Therefore accurate evaluation of HER2 status is important in treatment decision. Several 
methods are available for determination of HER2 protein overexpression or gene amplification (Penault-Llorca et al., 2009). 
HER2 status at protein level is assessed by immunohistochemistry (IHC), ELISA and Western blot.HER2 status at DNA level 
is determined by Southern blot, Slot blot, CISH, FISH, and MLPA. HER2 status assessment at RNA level is done by qRT-
PCR and microarray ( Moelans et al., 2011). Currently HER2 status is tested mostly by two methods: immunohistochemistry 
(IHC) and fluorescence in situ hybridization (FISH). FISH is considered as a preferable technique comparison to IHC because, 
stability of DNA as a target is higher than the HER2 protein. In addition, FISH is a quantitative interpretation and is easier for 
interlaboratory standardization (Sauter et al., 2009). Based on the findings of several studies, FISH technique has been 
determined as the most precise method for detection of HER2 gene ampliﬁcation and determination of response to HER2 
targeted therapy (Mass et al., 2005). Our objective in the present study was to assign HER2 gene status in patients with 
invasive breast cancer by FISH. Secondly, we determined the correlation between HER2 gene amplification and clinical 
features like tumor grad, tumor type, tumor size, axillary lymph node involvement and age of patient. 
 
Materials and Methods 
The study used formalin fixed paraffin embedded tissue blocks from 46 histologically proven invasive breast cancer 
cases. These cases were collected from Dr. Faghihi laboratory in Isfahan from November 2011 till May 2012. This study was 
approved by the institutional ethics committee of Isfahan University. All patients were informed and they signed standardized 
written consent. Clinical data including tumor type, tumor grade, tumor size, lymph node status and age of patients, if possible, 
were provided for cases from file of patients in the hospital. Assessment of HER2 gene status was done by the Zytolight SPEC 
HER2/CEN17 dual color probe kit (ZytoVision, Bremerhaven, Germany). The probe contains green-labeled polynucleotides 
(ZyGreen: excitation at 547 nm and emission at528 nm) which target the HER2 gene and orange labeled polynucleotides 
(ZyOrange: excitation at 547 nm and emission at 572 nm) which target alpha-satellite-sequences of the centromere of 
chromosome 17. FISH procedure was performed according to the manufacture´s instruction. Subsequently, duplex formation 
of the fluorescent-labeled probe was assessed using Olympus BX5 florescent microscope (Olympus, Tokyo, Japan) fitted with 
suitable filters for spectrum orange, spectrum green and DAPI. The 4 µm sections were drown up onto silane-coated slides. 
Slides were incubated for 10 min at 70ºC on a hot plate and deparafinized for 2× 10 minutes in xylene (Merck KGaA, 
Darmstadt, Germany). After dehydration in decreasing concentration of ethanol (100%,100%, 90%, 70%) each for 5 minutes 
and washing in distilled water 2 × 2 minutes , the slides were immersed in pre-warmed heat pretreatment solution citric 
provided in the kit at 98ºC for 15 minutes then slides were washed for 2× 2 minutes in distilled water and drained off. Pepsin 
solution was applied to the tissue section and slides were incubated for 10 minutes in a humidity chamber. After enzymatic 
digestion the slides were rinsed in wash buffer SSC for 5 minutes and in distilled water for 1 minute and dehydrated in ethanol 
70%, 90% and 100% each for 1 minute. Determination of digest degree was done by applying 10µl DAPI and slides were 
evaluated under florescent microscope. After pretreatment a ready-to-use dual color probe consisting of HER2 HER2/neu and 
chromosome 17 probe was applied. The slides were covered with a cover slip and heated for 10 minutes at 75ºC on a hot plate 
for denaturation. The slides were incubated overnight at 37ºC in a humidity chamber. Post hybridization washing was carried 
out followed by washing in 1x wash buffer provided in the kit for 2 x 5 minutes at 37ºC. Slides were dehydrated in graded 
series of ethanol (70%, 90%, 100%) each for 1minute and air dried. Then the slides were counterstained with 30µl DAPI. The 
FISH specimens were analyzed using by Olympus BX5 florescent microscope (Olympus, Tokyo, Japan). In each case the 
number of HER2 signals and CEP17 signals were enumerated in 40 morphologically intact and no overlapping nuclei. The 
ratio of the number of HER2 signals to the number of chr17 signals per nucleus was used to score (Penault-Llorca et al., 2009). 
According to ASCO/CAP guidelines ratio of HER2 to CEP17 of >2.2 was considered as HER2 gene amplification, FISH ratio 
of <1.8 was interpreted as negative and FISH ratio of 1.8-2.2 was considered equivocal (Wolff et al., 2006). 
Statistical analysis: The association between HER2 status and clinical features like tumor grade, tumor type, tumor size, 
axillary lymph node involvement and age of patients was done using Chi squared test at the 0.05 level of significance (p 
value).  
 
Results and Discussion  
Gene amplification was evaluated in 46 formalin fixed paraffin embedded invasive breast cancer tissues by FISH. 
Twelve cases (26%) showed amplification of HER2 gene and in the rest of the samples (34 or74%) amplification was not 
detected. In the present study, there were no equivocal FISH results. Clinical and histological features of the patients are shown 
in Table 1. Based on Statistical analysis there was association between tumor grade and HER2status (p value=0.02) .HER2 
gene amplification was observed in tumors with high pathological grade. While ductal carcinoma cases had HER2 gene 
amplification more frequently (83.3%) than other types of breast cancer, no significant correlation was seen between tumor 
type and HER2 status. HER2status was not associated with tumor size, lymph node status and age of patients.  Clinically in 
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breast cancer, HER2 gene amplification has diagnostic and prognostic usefulness. The overexpression of the HER2 protein 
following the  HER2 gene amplification results in increased breast cell proliferation, survival and motility, all of which can 
lead to the  formation of a malignant breast tumor( Ross  et al., 2009; Badache and Gonçalves., 2006 ). Human breast cancers 
with HER2 gene amplification are highly aggressive and resistant to traditional treatments(Slamon et al., 1987; Yu et al.,2000 
). Trastuzumab, a recombinant humanized monoclonal antibody, downregulates HER2 and inhibits HER2 induced signaling 
cascades hence, prevents  proliferation of human breast cancer cells with amplified HER2 (Hudziak et al., 1987). Trastuzumab 
remarkably increases the survival of patients with HER2 positive cancer but despite the efficacy of trastuzumab, it has 
deleterious side-effects. Therefore accurate assessing of HER2 status for identifying patients whose tumors are amplified for 
the gene and respond toanti-HER2 therapy is indispensable for treatment decision. FISH and IHC are the most used techniques 
for HER2 status evaluation (Wolff et al., 2006). In terms of methodological and biological aspects, FISH technique is 
considered as a primary HER2 status testing in patients with breast cancer (Sauter et al., 2009). This technique is a rapid, 
accurate and reproducible method for HER2status assessment. Estimations about the proportion of HER2 gene amplification in 
breast cancer in different studies is in the range of 18%-30% (Wolff et al., 2006;  Slamon et al., 1989 ). In the present study, 
26% of patients had gene amplification; this is consonant with the results of other studies. In invasive breast cancer,HER2 
amplification occurs at significantly higher level in ductal carcinomas than in lobular carcinomas (Hoff et al., 2002; Ariga  et 
al., 2005) and HER2 amplification is known to have inverse correlation with the lobular tumor type (Bane et al., 2005). In this 
study, HER2 gene amplification was observed more frequently in cases with invasive ductal carcinoma tumors but there was 
no significant correlation between tumor type and HER2 status. Some prior studies have reported association between HER2 
amplification and prognostic factors such as tumor size (Borg et al., 1990) and axillary lymph node involvement (Borg et al., 
1990; Gusterson  et al., 1992). In the present study, no correlation was observed between tumor size, lymph node status and 
HER2 gene amplification. These findings are concordant with reported results in existing literature (Panjwani et al., 2010;  
Prati et al., 2005). No significant relationship was found between HER2 gene amplification and age of patients as previous 
studies (Pinto et al., 2001; SezgÄN Ramadan et al., 2011). Panjwani et al and Yau et al  have reported a correlation between 
HER2 amplification and tumor grade (Panjwani et al., 2010; Yau  et al., 2008). Statistical analysis in this study also showed 
concordance between HER2status and tumor grade. It has been showed that 97% of cases with HER2 gene amplification have 
grade II and III. 
In conclusion, the result of this study like the findings of other studies showed presence of HER2 gene amplification 
in invasive breast cancer. Also, the association between HER2 gene amplification and tumors with high pathological grade 
indicate poor prognosis of this kind of tumors and supplication of HER2 assessment for efficient management of disease and 
selection of useful treatment.  
 
Table 1. Clinical and histological characteristics of 46 invasive breast cancer patients 
Characteristic Number of patients (%) 
Age (yr) 
≤50 
>50 
 
30(65.2) 
16(34.8) 
Tumor size(cm) 
<2 
≥2 
Uncertain 
 
17(37) 
20(43.5) 
19(19.5) 
Histological type 
Ductal 
Lobular 
Other 
 
29(63) 
7(15.2) 
10(21.7) 
Histological grade 
Grade 1 
Grade 2 
Grade 3 
Uncertain 
 
5(10.9) 
19(41.3) 
15(32.6) 
7(15.2) 
Lymph node status 
Positive 
Negative 
Uncertain 
 
20(43.5) 
14(30.14) 
12(26.1) 
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